// App-Quantinova.ai

TPS5106 : Targeting reciprocal feedback inhibition in the clinic: ARN509 and PI3K pathway inhibition in patients with metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Dana E. Rathkopf

Principal Investigators

  • Brett Stewart Carver

  • Susan F. Slovin

  • Karen A. Autio

  • Mia DeNunzio

  • Charles L. Sawyers

  • Howard I. Scher

  • Yu Chen

  • Michael J. Morris

  • Daniel Costin Danila

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Memorial Sloan Kettering Cancer Center, Brooklyn, NYSidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NYMemorial Sloan-Kettering Cancer Center, New York, NY

  • Human Oncology and Pathogenesis Program, Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY

  • Human Oncology and Pathogenesis Program, Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • 18F-fluorodeoxyglucose

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Circulating tumor cells

Drug/Treatment

  • CB-7598

  • Everolimus

  • Prednisone

  • Androgen Tear

  • ARN-509

  • taxane

Outcome

  • Unknown

Study Design

  • pharmacokinetics

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved